Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST101 (Lerodalcibep) Phase 1 Safety and PK/PD in Healthy Chinese Participants with Elevated LDL-C
NCT06504043Phase 1Enrolling by invitation
- Sponsor
- Hasten Biopharmaceuticals
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lerodalcibep in hypercholesterolemia (3 arms), sponsored by Hasten Biopharmaceuticals. Primary endpoint: Safety and Tolerability at 57 days. Started Sep 2024; status: enrolling by invitation.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06504043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504043.